Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904 New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro Results to be presented at American Association for Cancer Research (AACR) Virtual Annual Meeting II Montreal, Canada – May 15, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: …Lire la suite

Theratechnologies Announces New Positive Results For Two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

TH1902 and TH1904 more effective and safer in vivo compared to current standard ovarian cancer treatments  New data presented during the AACR Virtual Annual Meeting Montreal, Canada – April 27, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that new positive results about its two investigational peptide-drug conjugates …Lire la suite

Message from the President and CEO

As each and everyone of us is concerned with the current global pandemic, our goal at Theratechnologies remains, more than ever, to ensure that people living with HIV have access to our treatments. We have ample inventory to meet demand and our supply chain is up and running normally. People with an uncontrolled HIV are …Lire la suite

Theratechnologies To Make Oral Presentation On Oncology Platform During AACR Virtual Annual Meeting

Montreal, Canada – April 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it will make an oral presentation on new results from its sortilin targeting oncology platform during a virtual session of the annual meeting of the American Association for Cancer Research (AACR).

Theratechnologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Montreal, Canada – April 16, 2020 – Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common  shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). …Lire la suite

Theratechnologies Announces Financial Results For The First Quarter of 2020

Montreal, Canada – April 14, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the first quarter ended February 29, 2020.  First quarter 2020 financial highlights First quarter net sales of $15,719,000, up 4.1% from the same quarter last year Trogarzo® sales up 17.4% from …Lire la suite

Theratechnologies responses to current COVID-19 pandemic

Ensuring patient access and product supply: Theratechnologies Inc. has enough inventory to provide TROGARZO®, EGRIFTA SVTM or EGRIFTA® to existing and new patients for the next 12 months. Production of TROGARZO®, EGRIFTA SVTM or EGRIFTA® has not been affected by the COVID-19 situation. The Department of Health and Human Services (DHHS) issued on Friday March …Lire la suite